SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

10443	Companies
219247	Keywords
148701	Articles
115972	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 07/16/2025 at 07:00, 10 months 7 days ago

Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
Sanofi's SAR446597 receives fast track designation in the US for geographic atrophy due to age-related macular degeneration, aiming to address unmet medical needs with innovative gene therapy

Gene Therapy Sanofi Fast Track Designation Geographic Atrophy SAR446597
PRESS RELEASE

published on 07/15/2025 at 18:30, 10 months 8 days ago

Sanofi: Disclosure of trading in own shares
PRESS RELEASE

published on 06/30/2025 at 21:33, 10 months 23 days ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 06/30/2025 at 07:35, 10 months 23 days ago

Sanofi Releases Q2 2025 Aide Mémoire

Forward-looking Statements Investor Information Financial Modeling Aide Mémoire Sanofi Q2 2025
PRESS RELEASE

published on 06/30/2025 at 07:30, 10 months 23 days ago

Press release: Availability of the Q2 2025 Aide mémoire
Sanofi releases Q2 2025 Aide mémoire for financial modelling, to be published on July 31, 2025. Company details its commitment to innovation and impact in healthcare

Innovation Sanofi Aide Mémoire Financial Modelling Q2 2025
BRIEF

published on 06/25/2025 at 07:05, 10 months 28 days ago

Riliprubart Granted Orphan Drug Designation in the United States

FDA Immunology Orphan Drug Riliprubart Kidney Transplant
PRESS RELEASE

published on 06/25/2025 at 07:00, 10 months 28 days ago

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
Sanofi's riliprubart granted orphan drug designation by FDA for antibody-mediated rejection in solid organ transplantation, addressing critical unmet need in transplant medicine

Orphan Drug Designation Sanofi Riliprubart Antibody-mediated Rejection Solid Organ Transplantation
BRIEF

published on 06/23/2025 at 07:05, 11 months ago

Sarclisa Gains EU Recommendation for Multiple Myeloma Treatment

Multiple Myeloma Phase 3 Study Sarclisa CHMP Approval Induction Therapy
PRESS RELEASE

published on 06/23/2025 at 07:00, 11 months ago

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by CHMP for transplant-eligible newly diagnosed multiple myeloma based on GMMG-HD7 study. Potential to improve outcomes in frontline setting globally

Multiple Myeloma Sarclisa EU Approval GMMG-HD7 Study CHMP Recommendation
BRIEF

published on 06/20/2025 at 07:05, 11 months 3 days ago

FDA Approves Dupixent for Bullous Pemphigoid Treatment

FDA Approval Dupixent Type 2 Inflammation Bullous Pemphigoid Rare Skin Disease

Accesswire

Published on 05/23/2026 at 19:45, 4 hours 42 minutes ago

Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 21 hours 12 minutes ago

UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 21 hours 27 minutes ago

Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 22 hours 2 minutes ago

Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 22 hours 2 minutes ago

Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec

View all ACCESSWIRE

EQS Group

Published on 05/23/2026 at 16:30, 7 hours 57 minutes ago

HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 8 hours 30 minutes ago

EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 1 day 2 hours ago

Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 1 day 4 hours ago

Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/22/2026 at 18:33, 1 day 5 hours ago

Update on Coupon payment due on 23 May 2026 and Preparation of the Green Bond Restructuring

Les Echos

Published on 05/22/2026 at 18:05, 1 day 6 hours ago

Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 11 hours ago

Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
Published on 05/22/2026 at 08:30, 1 day 15 hours ago

Eiffage is building four solar power plants for the NOOR Atlas programme in Morocco
Published on 05/21/2026 at 17:50, 2 days 6 hours ago

CDA - H1 results 2025 2026
Published on 05/21/2026 at 17:45, 2 days 6 hours ago

CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS

View all LES ECHOS COMFI WIRE